US stock · Healthcare sector · Biotechnology
Company Logo

ImmunoGen, Inc.

IMGNNASDAQ

3.54

USD
-0.03
(-0.84%)
After Hours Market
-7.06P/E
-5Forward P/E
-0.27P/E to S&P500
780.697MMarket CAP
- -Div Yield

ImmunoGen, Inc.

NASDAQ:IMGN

RECENT
PRICE

3.54

P/E
RATIO

-7.06

(PEG:0.04)

P/E RATIO
RELATIVE
TO S&P

-0.27

DIV
YLD

0.00%

High:
Low:

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

0
0

Legends

Stock price

1.24 Beta (1.0 Market)

0

0

0

0

0

0

0

0

0

-

% total return 05/22:

Stock

S&P

1y.

0

0

3y.

0

0

5y.

0

0

0

Percent shares traded:

0

0

0

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

2018

2019

2020

2021

TTM

Fiscal year

0.78

(0.43)

(0.40)

- -

0.92

(0.45)

(0.43)

- -

0.94

(0.75)

(0.89)

- -

0.55

(0.63)

(0.30)

- -

0.24

(0.87)

(0.72)

- -

0.28

(0.85)

(0.15)

- -

0.21

(0.95)

(0.48)

- -

0.42

(0.87)

(0.76)

- -

0.70

(0.83)

(0.72)

- -

0.99

(0.71)

(0.73)

- -

0.69

(1.67)

(1.55)

- -

1.18

(0.98)

0.07

- -

0.38

(1.21)

(1.23)

- -

0.55

(0.70)

(0.62)

- -

0.75

(0.25)

(0.45)

- -

0.34

(0.68)

(0.83)

- -

0.42

(0.60)

(0.76)

- -

Revenue per share

Earnings per share

Free Cash Flow per sh

Dividends per share

0.05

1.76

0.05

1.40

0.42

1.29

0.04

1.31

0.03

1.73

0.03

2.03

0.04

1.09

0.04

1.45

0.10

0.89

0.09

0.41

0.12

(0.95)

0.01

(0.18)

0.04

0.08

0.02

(0.51)

0.01

0.51

0.01

1.58

0.00

0.89

CAPEX per share

Book Value per share

41

42

43

51

59

69

77

84

85

86

87

98

140

148

176

206

218

Comm.Shares outs.(m)

(9.5)

(0.5)

- -

(11.0)

(0.6)

- -

(5.2)

(0.2)

- -

(11.5)

(0.2)

- -

(9.2)

(0.4)

- -

(13.3)

(0.8)

- -

(14.6)

(1.0)

- -

(18.6)

(1.1)

- -

(14.7)

(0.8)

- -

(16.0)

(0.8)

- -

(3.0)

(0.1)

- -

(5.3)

(0.2)

- -

(7.6)

(0.3)

- -

(4.6)

(0.2)

- -

(18.6)

(0.5)

- -

(10.2)

(0.3)

- -

(7.1)

(0.3)

- -

Avg. annual P/E ratio

P/E relative to S&P500

Avg. annual div. yield

Capital Structure (31/3/22 | Q1)

Total liabilities
$175 m.

Total assets
$482 m.

Long-term debt
$14 m.

Cash and equiv.
$438 m.

Goodwill - -

Retained earnings $(1,495) m.

Common stock 253 m. shares

Market Capitalisation
$795 m. (as of 24/5/22)

19

(311.8)%

16

(447.9)%

36

(205.5)%

60

(119.4)%

86

(63.7)%

60

(208.3)%

115

(51.1)%

53

(302.1)%

82

(112.0)%

132

(16.9)%

70

(179.0)%

92

(179.2)%

Revenue (m)

Operating margin

5

(58)

5

(73)

5

(73)

5

(71)

6

(61)

5

(145)

6

(96)

7

(169)

4

(104)

2

(44)

- -

(139)

1

(129)

Depreciation (m)

Net profit (m)

- -

(301.9)%

- -

(448.2)%

- -

(204.9)%

- -

(119.1)%

- -

(71.0)%

- -

(241.4)%

- -

(83.2)%

- -

(315.9)%

- -

(126.6)%

- -

(33.5)%

- -

(199.4)%

- -

(195.8)%

Income tax rate

Net profit margin

187

- -

140

150

- -

84

182

- -

122

130

- -

76

256

- -

35

193

100

(82)

221

2

(18)

208

2

11

131

2

(76)

202

19

90

378

- -

326

373

14

306

Working capital (m)

Long-term debt (m)

Equity (m)

(28.7)%

(26.8)%

(41.6)%

(44.7)%

(40.7)%

(87.4)%

(37.4)%

(34.1)%

(59.8)%

(49.5)%

(43.2)%

(94.3)%

(19.9)%

(17.6)%

(173.0)%

(55.3)%

(43.4)%

176.0%

(33.2)%

(26.9)%

536.5%

(70.4)%

(53.5)%

(1,538.9)%

(55.2)%

(37.0)%

136.8%

(9.1)%

(6.0)%

(49.5)%

(29.7)%

(24.0)%

(42.8)%

(30.1)%

(24.8)%

(42.2)%

ROIC

Return on capital

Return on equity

Working Capital

2019

2020

2021

Cash assets

176

294

479

Receivables

27

22

- -

Inventory

- -

- -

- -

Other

5

8

- -

Current assets

209

324

479

Acc. Payable

10

10

- -

Debt due

3

5

- -

Other

65

108

101

Current liab.

77

122

101

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

100.0%

- -

Plowback ratio

Div.&Repurch. to FCF

ImmunoGen, Inc. (US) started trading on November 5, 1989 (cik: 0000855654), operates in the Healthcare sector (Biotechnology industry), has 106 full-time employees, and is led by Mr. Mark Enyedy. ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts.

Annual rates

(avg rate of change)

Past
5 y.

Past
10 y.

Revenues

3.46%

33.89%

Cash flow

-668.54%

-288.20%

Earnings

48.52%

31.25%

Dividends

- -

- -

Book value

-227.31%

-152.03%

Insider trading

Type

Shares

Date

Mccain Tracey L

Award

44,000

11/15/22

Mccain Tracey L

Award

30,000

11/15/22

Goldberg Mark Alan

Award

3,151

03/31/22

Mitchell Dean J

Award

3,151

03/31/22

Mccain Tracey L

Award

2,888

03/31/22

Fiscal Year Ends

Quarterly Revenue (m)

Full fiscal year

I

II

III

IV

2020

13

15

18

86

132

2021

16

17

9

28

70

2022

38

- -

- -

- -

- -

Fiscal Year Ends

Earnings per share

Full fiscal year

I

II

III

IV

2020

(0.17)

(0.14)

(0.13)

0.18

-0.25

2021

(0.17)

(0.15)

(0.18)

(0.18)

-0.68

2022

(0.10)

- -

- -

- -

- -

Fiscal Year Ends

Quarterly dividends paid

Full fiscal year

I

II

III

IV

2020

- -

- -

- -

- -

- -

2021

- -

- -

- -

- -

- -

2022

- -

- -

- -

- -

- -

02/15/2022

Virgin Galactic, Tower Semiconductor, CrowdStrike, Bitcoin: What to Watch in the Stock Market Today

The Wall Street Journal - Read more...